Translocation Studies Mid-Term Review (MTR) Meeting Marseille, France

Similar documents
Update on CLSI and EUCAST

Expert rules in antimicrobial susceptibility testing: State of the art

Expert rules. for Gram-negatives

Cefotaxime Rationale for the EUCAST clinical breakpoints, version th September 2010

Antibiotic Resistance Pattern of Blood and CSF Culture Isolates At NHLS Academic Laboratories (2005)

Discussion points CLSI M100 S19 Update. #1 format of tables has changed. #2 non susceptible category

Infection & Chemotherapy. Original Article

University of Alberta Hospital Antibiogram for 2007 and 2008 Division of Medical Microbiology Department of Laboratory Medicine and Pathology

Antibacterial-Resistant Pseudomonas aeruginosa: Clinical Impact and Complex Regulation of Chromosomally Encoded Resistance Mechanisms

Development of Resistance mechanisms in Pseudomonas aeruginosa

Role of efflux pump inhibitor in decreasing antibiotic cross-resistance of Pseudomonas aeruginosa in a burn hospital in Iran

Cefuroxime iv Rationale for the EUCAST clinical breakpoints, version th September 2010

This material is supported in part by unrestricted educational grants from: Abbott, Bayer HealthCare, Merck Frosst, Roche Diagnostics, and Wyeth Inc.

Prevalence of Extended Spectrum -Lactamases In E.coli and Klebsiella spp. in a Tertiary Care Hospital

Laboratory CLSI M100-S18 update. Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator

Molecular mechanisms of antibiotic resistance in Neisseria gonorrhoeae

Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory, Institute of Environmental Science and Research Limited (ESR); July 2014.

Sep Oct Nov Dec Total

Development of C sporins. Beta-lactam antibiotics - Cephalosporins. Second generation C sporins. Targets - PBP s

ALERT. Clinical microbiology considerations related to the emergence of. New Delhi metallo beta lactamases (NDM 1) and Klebsiella

Affinity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and ACCEPTED

NONFERMENTING GRAM NEGATIVE RODS. April Abbott Deaconess Health System Evansville, IN

Adenium Biotech. Management: - Peter Nordkild, MD, CEO, ex Novo Nordisk, Ferring, Egalet - Søren Neve, PhD, project director, ex Lundbeck, Novozymes

Other β-lactam. A. Carbapenems:

/01/$ DOI: /JCM Copyright 2001, American Society for Microbiology. All Rights Reserved.

Antibiotic Treatment of GNR MDR Infections. Stan Deresinski

High Incidence of Multidrug Resistant Pseudomonas aeruginosa Isolated from Infected Burn Wounds in a Tertiary Hospital

Resistance to Polymyxins in France

Role of charged residues of E. coli porins studied using planar lipid bilayers

β-lactamase inhibitors

Disclosure. Objectives. Evolution of β Lactamases. Extended Spectrum β Lactamases: The New Normal. Prevalence of ESBL Mystic Program

(multidrug-resistant Pseudomonas aeruginosa; MDRP)

Overcoming the PosESBLities of Enterobacteriaceae Resistance

HUSRES Annual Report 2009 Martti Vaara

Macrolides, Clindamycin & Ketolides Polymyxins

Carbapenemases in Enterobacteriaceae: Prof P. Nordmann Bicêtre hospital, South-Paris Med School

Downloaded from ismj.bpums.ac.ir at 10: on Friday March 8th 2019

Phenotypic detection of ESBLs and carbapenemases

Pseudomonas aeruginosa: from environment to humans

Conessine as a novel inhibitor of multidrug efflux pump systems in Pseudomonas aeruginosa

Author: Souha Kanj Andrew Whitelaw Michael J. Dowzicky. To appear in: International Journal of Antimicrobial Agents

Annual Surveillance Summary: Pseudomonas aeruginosa Infections in the Military Health System (MHS), 2016

Emergence of non-kpc carbapenemases: NDM and more

MHSAL Guidelines for the Prevention and Control of Antimicrobial Resistant Organisms (AROs) - Response to Questions

Shirin Abadi, B.Sc.(Pharm.), ACPR, Pharm.D. Clinical Pharmacy Specialist & Pharmacy Education Coordinator, BC Cancer Agency Clinical Associate

Carbapenem-resistant Escherichia coli and Klebsiella pneumoniae in Taiwan

PREVENTIVE MEDICINE - LABORATORY

Analysis of the common opportunistic pathogens

Issues Abx request. Sneezing w/ post- nasal d/c & redness mucous membranes Throat. Chest px w/ coughing, difficulty breathing

Infection Control Strategies to Avoid Carbapenam Resistance in Hospitals. Victor Lim International Medical University Malaysia

What is new in EUCAST South Africa, May, Gunnar Kahlmeter EUCAST Technical Data Coordinator and Webmaster Sweden

Hypoxia increases antibiotic resistance in Pseudomonas aeruginosa. through altering the composition of multidrug efflux pumps.

Surveillance of antimicrobial susceptibility of Enterobacteriaceae pathogens isolated from intensive care units and surgical units in Russia

Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria from ICU Patients with Pneumonia

ST11 KPC-2 Klebsiella pneumoniae detected in Taiwan

Rapid detection of carbapenemase-producing Pseudomonas spp.

Mechanisms of Bacterial Resistance to Antibiotics in Infections of COPD Patients

Extended-Spectrum -Lactamases: a Clinical Update

Nightmare Bacteria. Disclosures. Technician Objectives. Pharmacist Objectives. Carbapenem Resistance in Carbapenem Resistance in 2017

Chalhoub et al. Avibactam and resistance mechanisms in P. aeruginosa - Page 1 of 17

Detecting CRE. what does one need to do?

Screening and detection of carbapenemases

Clinical Microbiology Newsletter

A Snapshot of Colistin Use in South-East Europe and Particularly in Greece

In Vitro Susceptibility Pattern of Cephalosporin- Resistant Gram-Negative Bacteria

Veterinary and Agrochemical Research Centre

Efflux Pumps, OprD Porin, AmpC -Lactamase, and Multiresistance in Pseudomonas aeruginosa Isolates from Cystic Fibrosis Patients

Treatment Strategies for Infections due to MDR-GNR

Guidance on screening and confirmation of carbapenem resistant Enterobacteriacae (CRE) December 12, 2011

Determining the Optimal Carbapenem MIC that Distinguishes Carbapenemase-Producing

Tigecycline activity tested against 26, 474 bloodstream infection isolates: a collection from 6 continents

Phenotypic Detection Methods of Carbapenemase Production in Enterobacteriaceae

Consultation on the Revision of Carbapenem Breakpoints

Rapid identification and resistance assessment: The future is mass spectrometry

ESCMID Online Lecture Library. by author

Detecting carbapenemases in Enterobacteriaceae

AAC Accepts, published online ahead of print on 13 October 2008 Antimicrob. Agents Chemother. doi: /aac

Public Health Surveillance for Multi Drug Resistant Organisms in Orange County

Sepsis Treatment: Early Identification Remains the Key Issue

Annual Surveillance Summary: Pseudomonas aeruginosa Infections in the Military Health System (MHS), 2017

Use of imipenem. with the support of Wallonie-Bruxelles International. Magali Dodémont Microbiology Hospital Erasme Université Libre de Bruxelles

In Vitro Activity of Ceftazidime-Avibactam Against Isolates. in a Phase 3 Open-label Clinical Trial for Complicated

Academic Perspective in. David Livermore Prof of Medical Microbiology, UEA Lead on Antibiotic resistance PHE

Aminoglycosides. Not orally absorbed. Interact with negatively charged lipopolysaccharide on Gram- cell wall. Aminoglycoside properties

Antibiotic Usage Related to Microorganisms Pattern and MIC

Carbapenemase-producing Enterobacteriaceae

β- Lactamase Gene carrying Klebsiella pneumoniae and its Clinical Implication

Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Hong Kong. Title. Ho, PL; Tse, CWS; Lai, EL; Lo, WU; Chow, KH

Journal of Infectious Diseases and

In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria

(Plasmid mediated) Carbapenemases. Timothy R. Walsh, Cardiff University, Wales

Diagnosis of CPE: time to throw away those agar plates? Jon Otter, PhD FRCPath Guy s and St. Thomas NHS Foundation Trust / King s College London

Continuous Infusion of Antibiotics In The ICU: What Is Proven? Professor of Medicine Vice-Chairman, Department of Medicine SUNY at Stony Brook

Summary of Product Characteristics

Urinary Tract Infections: From Simple to Complex. Adriane N Irwin, MS, PharmD, BCACP Clinical Assistant Professor Ambulatory Care October 25, 2014

Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria

National Center for Emerging and Zoonotic Infectious Diseases The Biggest Antibiotic Resistance Threats

Summary of Product Characteristics

The b-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter

Urinary Tract Infection and Pattern of Antibiotic Sensitivity in Hospitalized Patients with Diabetes Mellitus in Myanmar

Transcription:

Marie Curie Actions Research Training Networks (RTN) Translocation Studies Mid-Term Review (MTR) Meeting Marseille, France F. Vidal-Aroca, M.G.P. Page and J. Dreier

Background Deteriorating situation regarding treatment of Gram-negative infections Growing concern over: Multi-resistant Acinetobacter Multi-resistant Pseudomonas aeruginosa Carbapenem-resistant Klebsiella pneumoniae ESBL-producing K. pneumoniae and Escherichia coli Warnings for: Carbapenem-resistant Enterobacter GNNFs like Burkholderia, Stenotrophomonas.

Interests & Expectations at Basilea Insight into the permeation of β-lactam antibiotics in clinical isolates Permeation route(s) of novel compounds Role of porins in resistance Role of efflux systems in resistance

Rationale Focus on the role of porins and efflux systems in antibiotic resistance of Gram-negative bacteria Antibiotic Uptake Efflux Antibiotic-resistant Cells

Permeability of Bridged Monobactams R1 O H O N N O S R2 H O O Bridged monobactams are potent β- lactamase inhibitors When R2 = H, activity against β- lactamase in situ can be modulated by R1 When R2 = OMe or larger, all activity against β-lactamase in situ is lost, irrespective of R1

Permeability of Bridged Monobactams R2 IC 50 β- lactamase in vitro (mm) MIC against cells in situ Effect on OMPF Conductance (from Mathias) RO 47-7303 OCH 3 0.06 >64* No interaction RO 47-0243 CH.CONH 2 0.05 >64* Blocking RO 46-9392 Cl 0.1 >64* No interaction RO 46-8377 S-tetrazole 0.009 >64* Blocking RO 44-4454 H 0.1 2* No effect Carbenicillin - - 4 No interaction Penicillin G - - 16 Some blocking * In combination with penicillin

Permeability of Bridged Monobactams Is the lack of correlation due to OmpC? Knock-out strain with only OmpF Need more data points to look for trends Select more penicillins with a spread of MIC values Select more bridged monobactams Are the conditions appropriate? low ph, high salt vs neutral ph, isotonic

Gene Disruption Gene target: ompc tolc Baba T. et al. Molecular Systems Biology (2006)

β-lactams Selected Meropenem Aztreonam Cefepime Ampicillin Penicillin G Carbenicllin

E. coli MIC Determination (I) Strain Ampicillin Aztreonam Carbenicillin 400mM NaCl 400mM NaCl 400mM NaCl ATCC25922 8 4 0.125 <=0.06 4 4 W3110 2 0.5-1 0.06 0.008-0.016 4 2 W3110:: omp C 4 2 0.125 0.06 16 8 W3110:: omp F 8 4 0.125 0.06 16 16 W3110: ompf ompc 8 4 0.25 0.125 32 32 Cefepime Meropenem Penicillin G Strain 400mM NaCl 400mM NaCl 400mM NaCl ATCC25922 0.03 0.008 0.06 0.03-0.125 >=32 16 W3110 0.016 <=0.002-0.004 0.008-0.016 0.008-0.016 16 4 W3110:: omp C 0.03 0.004 0.016 0.03 >32 8 W3110:: omp F 0.06 0.008 <=0.004 <=0.004 >32 32 W3110: ompf ompc 0.5 0.25 0.5 1 >32 16 tolc: MIC determination is ongoing

Conclusions 1. Equal contribution of OmpC and OmpF to aztreonam, ampicillin and carbenicillin susceptibilities. 2. Strong influence of the double K.O. mutant on cefepime and meropenem susceptibilities. 3. Weak influence of the single K.O. mutants on cefepime and meropenem susceptibilities. 4. High osmolarity potentiates the effect of cefepime > penicillin G > others.

Additional Antibiotic Classes Selected Gentamicin Ciprofloxacin Chloramphenicol Erythromycin Minocycline Polymyxin B

E. coli MIC Determination (II) Chloramphenicol Ciprofloxacin Erythromycin Strain 400mM NaCl 400mM NaCl 400mM NaCl ATCC25922 8 2-4 0.004 0.004 >32 >32 W3110 4 1-2 0.004 0.004 16 8 W3110:: omp C 8 4 0.004 0.004 >32 >=32 W3110:: omp F 32 4 0.016 0.016 >32 32 W3110: ompf ompc 8 4 0.016 0.016 >32 >32 Gentamicin Minocycline Polymyxin B Strain 400mM NaCl 400mM NaCl 400mM NaCl ATCC25922 0.5-2 4-8 0.5-1 0.5-1 2-4 1-4 W3110 0.5 1-2 1 1 0.5 1 W3110:: omp C 0.25 2 2 1 1 1 W3110:: omp F 0.25 1 4 2 1 1 W3110: ompf ompc 0.5 2 0.5 0.5 1 0.5

Conclusions 1. The susceptibility of E. coli to gentamicin or polymyxin B is NOT influenced by OmpF and OmpC porins. 2. Minocycline susceptibility is increased in the double K.O. mutant. 3. Deletion of OmpF slightly decreases the ciprofloxacin susceptibility. 4. Chloramphenicol and erythromycin data need to be confirmed

β-lactamase Inhibitors (BLI) Approach Strains with AmpC overexpressed SUSCEPTIBILITY SYNERGY PERMEABILITY OF BLI MICs β-lactams MICs β-lactams+bli IC 50 of β-lactamase in situ AmpC Contribution AmpC Inhibition Role of outer membrane & porins

BLI: β-lactam Selection Overexpression of AmpC in wt and porin mutant strains MIC determination led to the selection of the following β-lactams antibiotics for synergy test: aztreonam, penicillin G, ampicillin and carbenicillin The bacteria growth was not affected at concentrations of 256 mg/l of bridged monobactans tested The overexpression of AmpC does not influence the MIC of other classes of antibiotics.

I) Aztreonam Penicillin G Ampicillin Carbenicillin BLI: Experiments ongoing RO 47-0243 or RO 44-4454 (BLIs) wt omp C omp F omp C omp F - NaCl + NaCl - NaCl + NaCl - NaCl + NaCl - NaCl + NaCl Synergy assay II) Aztreonam Penicillin G Ampicillin Carbenicillin RO 47-0243 or RO 44-4454 (BLIs) wt ompc omp F omp C ompf - NaCl + NaCl - NaCl + NaCl - NaCl + NaCl - NaCl + NaCl Permeability assay

Pseudomonas aeruginosa Ubiquitous environmental bacterium One of the top causes of opportunistic human infections bacteraemia in burn victims urinary-tract infections hospital-acquired pneumonia AIDS population predominant cause of morbidity and mortality of cystic fibrosis patients Intrinsic resistance to antibiotics and disinfectants

Efflux Pumps Resistance Mechanism 1- Enzymatic inactivation 2- Alternative metabolic pathways 3- Reduced uptake 4- Alteration of the target site 5- Membrane bound efflux pumps Piddock L.J.V. Clin Microbiol Rev, Apr. 2006, p. 382 402

Efflux Systems in P. aeruginosa 7 of 12 RND-pump encoding operons in P. aeruginosa have been characterized: System Substrates MexAB/ OprM * MexXY/ OprM* MexCD/ OprJ* MexEF/ OprN* MexJK/ OprM Mex(G)HI/ OpmD MexVW/ OprM β-lactams, BLI, chloramphenicol, novobiocin, macrolides, quinolones, sulfonamides, tetracyclines, trimethoprim, thiolactomycin, detergents, triclosan, aminoglycosides, β-lactams, erythromycin, fluoroquinolones, tetracyclines, β-lactams, quinolones, chloramphenicol, novobiocin, sulfonamides, tetracyclines, trimethoprim, triclosan, fluoroquinolones, tetracycline, chloramphenicol, trimethoprim, triclosan ciprofloxacin, erythromycin, tetracycline, triclosan vanadium, norfloxacin, chloramphenicol, erythromycin, fluoroquinolones, tetracycline, * major contributors to MDR Other clinically relevant bacteria with RND efflux systems: A. baumannii, B. cepacia, B. pseudomallei, S. maltophilia, N. gonorrhoeae, N. meningitidis, S. marcescens, E. coli, S. enterica, E. aerogenes, K. pneumoniae, K. oxytoca, C. jejuni, P. mirabilis, H. influenzae.

Knock-out Mutants http://www.pseudomonas.com 1. Make single and multiple knock-out mutants of all major RND pumps in P. aeruginosa. Schweizer H.P. (2003) Genetics and Molecular Research 2(1):48-62 2. Measure susceptibility to all available antibiotics in comparison to the parent strain.

Disruption of various mex & opr genes Target gene A B B C 1 2 3 4 genomic DNA PCR 1/2 & 3/4 Cloning vector Gene replacement vector (Gm R, SacB) antibiotic resistant & sucrose sensitive antibiotic sensitive & sucrose resistant 1 st crossingover: 2 nd crossingover: Knock-out mutant (or reversal to wt)

P. aeruginosa Strains Studied Strain PAO1 PAO1 mexr PAO1 oprj Affected Efflux-pump Systems Wild type MexAB-OprM overexpression (commonly found in clinical isolates) Impaired assembly of MexCD-OprJ

P. aeruginosa MIC Determination (I) Strain Ampicillin Aztreonam Carbenicillin Cefepime ATCC27853 >128 4-8 64 2 PAO1 >128 2-8 128 2 PAO1/ mexr >128 32 >128 8 PAO1/ oprj >128 8 >=128 4 Strain Imipenem Meropenem Penicillin G Piperacillin ATCC27853 2 1 >128 8 PAO1 1-4 0.5-2 >128 4-8 PAO1/ mexr 4 8-16 >128 32 PAO1/ oprj 4 2-4 >128 8

Conclusions 1. Wild type efflux-pump expression caused high resistance to ampicillin, carbenicillin and penicillin G. 2. The mexab-oprm system strongly contributed to resistance towards piperacillin, aztreonam, meropenem and cefepime. 3. No contribution of the main pumps to imipenem resistance was observed. 4. The oprj K.O. mutant did not cause significant differences in β-lactam susceptibility.

P. aeruginosa MIC Determination (II) Strain Chloramphenicol Ciprofloxacin Erythromycin Gentamicin ATCC27853 >32 0.5 >32 1-2 PAO1 >32 0.125-0.25 >32 2 PAO1/ mexr >32 0.5-1 >32 2 PAO1/ oprj >32 0.125-0.25 >32 2 Strain Minocycline Moxifloxacin Polymyxin B ATCC27853 16 2 2 PAO1 16-32 1-2 2 PAO1/ mexr >32 8 2 PAO1/ oprj >=32 2 2

Conclusions 1. Wild type efflux-pump expression caused high resistance to chloramphenicol, erythromycin and minocycline. 2. The mexab-oprm system strongly contributed to resistance towards ciprofloxacin and moxifloxacin. 3. No contribution of the main pumps to gentamicin and polymyxin B resistance was observed. 4. The oprj K.O. mutant did not cause significant differences in susceptibility to the tested compounds.

Consortium Interactions Prof. Winterhalter Compounds sent for Conductance Measurements Summer School Participations Mircea Petrescu s Training Dr. Weingart Strains Exchange Basilea Pharmaceutica Prof. Gameiro Cephalosporins Provided for Measurements Dr. Ceccarelli & Prof. Ruggerone In silico Modeling: Porins & TolC Ph.D. Program Presentation

Acknowledgements UK Italy Dr. Bertoni Dr. Camara USA Prof. Schweizer All the Consortium People Basilea Dr. Shapiro Basilea Dr. Caspers